AGW 2016 Conference Review - focus on Hepatitis, reviewed by Dr. Robert Cheng

In this review:

Elbasvir/grazoprevir for HCV infected patients with CKD
Sofosbuvir/velpatasvir/ribavirin retreatment after NS5A failure
Sofosbuvir/daclatasvir in decompensated HCV cirrhosis
Is alfa-fetoprotein surveillance for HCC necessary?
Second-line mycophenolate in autoimmune hepatitis
Sustained virological response to HCV halts fibrosis progression
Elbasvir/grazoprevir in compensated cirrhosis HCV GT1, 4 or 6
Barriers to DAA prescribing for GPs
Predictive value of non-invasive scoring systems in NAFLD
Are indirect biomarkers enough for community treatment?

Please login below to download this issue (PDF)